CABLIVI Drug Insight

“CABLIVI Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about CABLIVI for thrombocytopenia in the seven major markets. A detailed picture of the CABLIVI for thrombocytopenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the CABLIVI for thrombocytopenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CABLIVI market forecast analysis for thrombocytopenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in thrombocytopenia.

Drug Summary

CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. It is approved in the US and EU for the treatment of aTTP.

Dosage

CABLIVI should be administered upon initiation of plasma exchange therapy. The recommended dose of CABLIVI is as follows:

First day of treatment: 11 mg bolus intravenous injection at least 15 min prior to plasma exchange, followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1.

Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once daily following plasma exchange.

Treatment after plasma exchange period: 11 mg subcutaneous injection once daily, continuing for 30 days following the last daily plasma exchange. If, after the initial treatment course, sign(s) of a persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.

Discontinue CABLIVI if the patient experiences more than 2 recurrences of aTTP, while on CABLIVI.

Mechanism of Action

Caplacizumab-yhdp targets the A1-domain of vWF and inhibits the interaction between vWF and platelets, thereby reducing both vWF-mediated platelet adhesion and platelet consumption.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CABLIVI description, mechanism of action, dosage and administration, research and development activities in thrombocytopenia.
• Elaborated details on CABLIVI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CABLIVI research and development activities in thrombocytopenia across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CABLIVI.
• The report contains forecasted sales of for thrombocytopenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for thrombocytopenia.
• The report also features the SWOT analysis with analyst views for CABLIVI in thrombocytopenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CABLIVI Analytical Perspective by DelveInsight

In-depth CABLIVI Market Assessment

This report provides a detailed market assessment of CABLIVI for thrombocytopenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

CABLIVI Clinical Assessment

The report provides the clinical trials information of CABLIVI for thrombocytopenia covering trial interventions, trial conditions, trial status, start and completion dates.

CABLIVI Report Highlights 

• In the coming years, the market scenario for thrombocytopenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CABLIVI dominance.
• Other emerging products for thrombocytopenia are expected to give tough market competition to CABLIVI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CABLIVI in thrombocytopenia.
• Our in-depth analysis of the forecasted sales data of CABLIVI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CABLIVI in thrombocytopenia.

Key Questions

• What is the product type, route of administration and mechanism of action of CABLIVI?
• What is the clinical trial status of the study related to CABLIVI in thrombocytopenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CABLIVI development?
• What are the key designations that have been granted to CABLIVI for thrombocytopenia?
• What is the forecasted market scenario of CABLIVI for thrombocytopenia?
• What are the forecasted sales of CABLIVI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to CABLIVI for thrombocytopenia?
• Which are the late-stage emerging therapies under development for the treatment of thrombocytopenia?